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Abstract
Background: Implementing effective interventions remain a lot of difficulties along all border regions. The emergence
of artemisinin resistance of Plasmodium falciparum strains in the Greater Mekong Subregion is a matter of great
concern. China has effectively controlled cross-border transmission of malaria and artemisinin resistance of P.
falciparum along the China-Myanmar border.
Methods: A combined quantitative and qualitative study was used to collect data, and then an integrated impact
evaluation was conducted to malaria control along the China-Myanmar border during 2007–2013.
Results: The parasite prevalence rate (PPR) in the five special regions of Myanmar was decreased from 13.6 % in March
2008 to 1.5 % in November 2013. Compared with the baseline (PPR in March 2008), the risk ratio was only 0.11 [95 %
confidence interval (CI), 0.09–0. 14) in November 2013, which is equal to an 89 % reduction in the malaria burden. Annual
parasite incidence (API) across 19 Chinese border counties was reduced from 19.6 per 10 000 person-years in 2006 to 0.9
per 10 000 person-years in 2013. Compared with the baseline (API in 2006), the API rate ratio was only 0.05(95 % CI, 0.04–
0.05) in 2013, which equates to a reduction of the malaria burden by 95.0 %. Meanwhile, the health service system was
strengthened and health inequity of marginalized populations reduced along the international border.
Conclusion: The effective collaboration between China, Myanmar and the international non-governmental organization
promptly carried out the core interventions through simplified processes. The integrated approaches dramatically
decreased malaria burden of Chinese-Myanmar border.
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Background
A population of 3.2 billion is currently at risk for malaria
infection on the globe [1]. The Greater Mekong
Subregion (GMS) is considered a hot-spot of malaria trans-
mission with around 70 % of the local population at risk of
contracting malaria [2, 3]. Within the GMS, China has
made extraordinary progress in malaria control [4] and
aims to eliminate malaria nationwide by 2020 [5]. On the
other hand, Myanmar, which shares a border of 2 185 km
with China, is still among the 31 highest burden malaria
countries in the world [2, 6]. Importantly, Myanmar ex-
ports malaria to its neighboring countries. This seriously
impedes progress of malaria elimination in these countries
[7]. Additionally, five of the six GMS countries, all except
China, have reported artemisinin resistance of Plasmodium
falciparum [1, 8–12].
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Malaria control and elimination together with attempts
to contain drug resistance have received much attention
along international borders, but effective interventions re-
main challenging [1, 5, 8]. From 2007 to 2013, intensive ef-
forts have dramatically reduced the number of malaria
cases and the parasite prevalence along China- Myanmar
border; meanwhile, the drug sensitivity of malaria parasites
has not changed significantly [13, 14]. Knowledge and les-
sons learnt from the border malaria control would benefit
the global health. In this context, an impact evaluation was
conducted on the cross-border malaria control program.
Methods
Study site and population
This study was conducted between January 2008 and
May 2014 across 19 border counties of Yunnan Province
in China and five special regions in Myanmar (Fig. 1).
The study population consisted of 4 687 896 Chinese in-
dividuals and 586 000 residents from Myanmar. Notably,
there were estimated 110 000 longer term migrants (≥
one month in Myanmar) from China based on the five
Special Regions of Myanmar, and 1.5 million short-term
migrants from both China and Myanmar who cross the
border frequently. More than 50 % of the study popula-
tion was ethnic minorities [15]. These groups could not
usually receive sufficient access to healthcare. Malaria
control services of the Myanmar Ministry of Health were
unable to effectively cover the five special regions due to
ongoing conflicts between the Governments of Union of
Myanmar and locally ethnical military.
Core interventions
The sixth and tenth rounds of the Chinese malaria pro-
grams within the Global Fund to fight AIDS, Tubercu-
losis and Malaria (GFATM) launched in July 2007. The
GFATM program established 68 border malaria posts
(BMP) at informal border crossing locations throughout
the 19 Chinese counties. The BMPs provided diagnosis
and treatment for malaria, long lasting insecticidal nets
(LLIN) and behavior change communication (BCC) for
the 1.5 million short-term migrants. The existing public
health facilities were responsible for malaria control of
the local residents across 19 border counties in China.
Health Poverty Action (HPA), an UK-based non-
government organization (NGO), established 80 mal-
aria diagnoses and treatment stations (MDTS) in the five
special regions of Myanmar. The MDTs provided diagno-
sis and treatment for the residents of Myanmar and the
Chinese longer term migrants who were based in the five
special regions of Myanmar. In order to address gaps in
public sector coverage in Myanmar, the GFATM programs
supported community-based services, including, diagnosis
and treatment in 102 selected private clinics in communi-
ties where MDTS were not available, 475 village malaria
workers (VMW) in remote and hyperendemic villages and
30 migrant malaria workers (MMW) in the communities
of Chinese longer term migrants. Meanwhile, HPA ran
outreach services incorporating LLIN distribution, BCC
and support supervision together. The outreach teams
trained peer health educators in villages, and supervised
operations of MDTS, VMWs and MMWs and gave tech-
nical support to them. HPA also worked with the local
governments to introduce regulations banning the sale of
the fake and sub-standard antimalarial drugs including ar-
temisinin monotherapy.
Study procedures
Data of process evaluation were collected monthly. In
China, the malaria case and its related information such
as demographic data and travel history (for identifying
the place of infection), were daily collected and reported
by “Chinese Information System for Disease Control and
Prevention (CISDCP)” [16]. The travel history was used
to identify the infection origin in those cross border
people. Malaria patients that had once been in Myanmar
within one month prior to laboratory diagnosis were de-
fined as imported malaria [5].
In five special regions of Myanmar, HPA’s Health Infor-
mation System which was established and maintained by
the GFATM programs collected and reported the number
of malaria cases every month. Meanwhile, cross-sectional
surveys were conducted to collect data on parasite preva-
lence among residents between January and March in
2008, 2009, 2010 and 2011; and between September and
November in 2012 and 2013. The study design was fixed
as described by Wang et al. [17].
The GFATM program supplied antimalarial drugs.
Dihydroartemisinin-piperaquine (DP) is the most com-
monly used artemisinin- based combination therapy
(ACT) for treatment of P. falciparum malaria. Chloro-
quine was commonly used for treatment of P. vivax mal-
aria. The sensitivity of P. falciparum to DP and the
sensitivity of P. vivax to chloroquine were in vivo moni-
tored [13, 14, 18–20].
From November 2013 to May 2014, qualitative study
consisting of focus group discussions (FGD) and semi-
structured in-depth interviews (SDI) were undertaken
to collect qualitative data for the beneficiary- and
community-based evaluation [21–23]. Four FGDs were
planned for stakeholders and eight FGDs for villagers,
8–10 participants each group. SDIs were planned to
administer to 26 key informants. The issues discussed
with participants in FGDs and key informants of SDIs
included change of malaria burden; impact on public
health, healthcare system and social equity; and finally,
challenges and recommendations for malaria control
in the border region.
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Statistical analysis
The data of core interventions were aggregated and ana-
lyzed every six months. The parasite prevalence rate (PPR)
and the annual parasite incidence (API) with 95 % confi-
dence intervals (CI) were calculated by Epi Info 7 (Centers
for Disease Control and Prevention, Atlanta, GA). Risk ra-
tios (RR) with 95 % CI in Myanmar were calculated by
using the PPR in March, 2008 as the reference. API rate
ratios (IRR) with 95 % CI were calculated by taking the
API of 2008 in Myanmar and the API of 2006 in China as
the reference respectively. Qualitative data analysis was
conducted by software TAMS 3.0. The data were encoded
based on emerging themes and then a codebook was cre-
ated. Trends in the data were identified by producing
matrices which combined and compared with information
collected from the different FGDs and key informants.
Fig. 1 Map of the study site and neighboring region
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Core interventions were successfully targeted residents
along the China-Myanmar border. Table 1 indicates the
numbers of core interventions, including LLINs distrib-
uted, diagnostic tests used, short-term migrants who re-
ceived piperaquine for preventive treatment, cases treated
with quality-assured ACTs and chloroquine- primaquine
(CQ-PQ).
Reduced malaria burden in Myanmar
The malaria burden was gradually reduced since the
start of the GFATM interventions in 2008. In Myanmar,
the PPR decreased from 13.6 % (95 % CI, 12.7–14.6 %)
in March, 2008 to 1.5 % (95 % CI, 1.2–2.0 %) in Novem-
ber, 2013 (Fig. 2). Compared with the baseline (PPR in
March 2008), the RR was only 0.11(95 % CI, 0.09–0.14)
in November 2013, which is equal to an 89 % reduction
in the malaria burden (Table 2). Additionally, the API
reduced from 417.4 (95 % CI, 408.6–426.3) per 10, 000
person-years in 2008 to 71.2 (95 % CI, 69.2–73.4) per 10,
000 person-years in 2013 (Fig. 3). Compared with the
API in 2008, API rate ratio (IRR) was only 0.17 (95 %
CI, 0.16–0. 18) in 2013 (Table 3). There was not any re-
ported malaria-related death during 2008–2013.
In Kachin Special Region II (KR2), stakeholders of FGDs
still listed malaria as the most important public health
problem. However, they said that the number of malaria
cases had been reduced dramatically, and that there were
no malaria-related deaths after intervention. Participants
of internally displaced people in Je Yang Hka and Hpun
Lum Yang said that “Malaria was the most life-threatening
disease before intervention in KR2. For instance, there
were more than 20 deaths of malaria in Ban Dong, a vil-
lage with approximately 4 000 residents in 2006”.
In eastern Shan Special Region IV (SR4), stakeholders
of FGDs described malaria as the most important public
health problem before the intervention. However, mal-
aria was just listed as the fourth or fifth one following
the intervention. Participants considered malaria as the
most burdensome communicable disease. They said that
P. falciparum malaria prevalence and mortality were very
high before the intervention, and currently, morbidity was
very low. The deputy director of the health department of
SR4 said that “the proportion of malaria was about 40–
60 % of outpatients before 2006”. The chief of the Health
Bureau of Nan Bang County of SR4 said that “many
people died of malaria prior to the intervention, and then
various people left Nan Bang because of malaria fearful-
ness. However, malaria is uncommon now; there is only
one or two imported malaria cases from other areas of
Myanmar”. Participants of Man Beng Long and Man Beng
Mai villages said that: “Malaria was the most common
Table 1 Amount of core interventions across Chinese-Myanmar border from 2008 to 2013
Core interventions 2007 2008 2009 2010 2011 2012 2013 Total
Five special regions of Myanmar (Target populations: a population of
586 000 local residents and about 110 000 Chinese immigrants in Myanmar)
Numbers of long-lasting insecticidal bed nets distributed 13 866 67 753 25 274 13 943 38 134 84 506 93 501 336 977
Number of febrile patients who received parasite-based diagnosis
(RDTs or microscopy)
10 706 116 163 13 0684 103 538 26 431 71 289 121 083 579 894
Number of malaria cases treated with ACTs 3 059 27 254 37 192 25 782 2 084 85 10 11 537 106 908
Number of malaria cases treated with CQ-PQ – 193 18 339 24 580 51 12 3 731 6 642 53 485
Health education
Number of community health education sessions organized – 537 579 637 301 187 651 2 892
Number of attendees of community health education sessions – 47 560 40 099 42 801 19 218 10 657 28 892 189 227
19 counties of China (Target populations: border-crossing migrants,
about 1,500,000 person-times each year)
Numbers of long-lasting insecticidal nets distributed to migrants 9 486 30 867 10 977 1 6275 2 0042 6 6922 3 1031 1 85600
Number of migrants who received preventive treatment 28 976 37 552 47 594 44 479 27 719 46 740 44 269 277 329
Number of migrant febrile patients who received Parasite-based
diagnosis (Microscopy)
41 126 75 495 106 234 91 332 70 040 70 690 67 168 522 085
Number of migrant malaria cases treated with ACTs 808 853 1 644 1 184 546 207 125 5 367
Number of migrant malaria cases treated with CQ-PQ 3 056 7 081 8 699 6 044 2 083 1 084 1 220 2 9267
Number of migrants who received IEC materials 36 649 152 989 88 453 98 295 161 194 108 542 211 316 857 438
Notes: RDT rapid diagnostic test, ACT artemisinin-based combination therapy, CQ-PQ chloroquine-primaquine, IEC information, education and communication
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disease prior to the intervention, 40 %–50 % of people
contracting malaria each year. Some families had three
or four malaria patients a year. However, malaria was
currently scarce. It was difficult to find a malaria pa-
tient among 100 people. Only men who ever worked in
the forest, such as lumbering workers, could contract
malaria”.
In Shan Special Region II (locally called Wa State), the
director of the health department said that “many
intervention activities had been carried out in Wa State.
The malaria prevalence was very low after these interven-
tions”. The project manager of HPA of Wa State said
that: “About twenty percent of febrile patients were
malaria prior to the intervention. In 2005, more than
300 malaria cases were confirmed by Rapid diagnosis
test (RDT) during three work days in Lian He Town-
ship. However, it was difficult to find malaria cases at
all there following the intervention”.
Fig. 2 Parasite prevalence rates in the five special regions of Myanmar from March 2008 to November 2013
Table 2 Change of risk ratios in five special regions of Myanmar from 2008 to 2013
Dates surveyed Plasmodium vivax Plasmodium falciparum Plasmodium spp.
Number Risk ratio (95 % CI] P- value Number Risk ratio (95 % CI] P- value Number Risk ratio (95 % CI] P- value
Jan-Mar, 2008 (Baseline,
n = 5585)
460 Reference – 299 Reference – 761 Reference –
Jan-Mar, 2009 (n = 3600) 172 0.58 (0.49–0.69) <0.0001 184 0.95 (0.80–1.14) 0.6452 358 0.73 (0.65–0.82) <0.0001
Jan-Mar, 2010 (n = 5090) 255 0.61 (0.52–0.71) <0.0001 161 0.59 (0.49–0.71) <0.0001 429 0.62 (0.55–0.69) <0.0001
Jan-Mar, 2011 (n = 4069) 69 0.21 (0.16–0.26) <0.0001 44 0.20 (0.15–0.28) <0.0001 113 0.20 (0.17–0.25) <0.0001
Sep-Nov, 2012 (n = 4561) 71 0.19 (0.15–0.24) <0.0001 27 0.11 (0.07–0.16) <0.0001 98 0.16 (0.13–0. 19) <0.0001
Sep-Nov, 2013 (n = 4517) 52 0.14 (0.11–0. 19) <0.0001 18 0.07 (0.05–0. 12) <0.0001 70 0.11 (0.09–0. 14) <0.0001
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Eliminating malaria in china
Most people of 19 border counties in China were at a
high risk of malaria infection prior to the interventions.
The API was 19.6 (95 % CI, 19.2–20.0) per 10 000
person-years in 2006, and then the API remarkably de-
clined to 0.9 (95 % CI, 0.8–1.0) per 10 000 person-years
in 2013 (Fig. 4). From 2006 to 2013, the number of
imported malaria cases of Yunnan Province of China
from Myanmar was 4 340, 2 291, 1 566, 1 524, 1 258,
734, 388, and 356, respectively. The proportion of
imported cases in total malaria cases increased from
48.9 % (95 % CI, 47.9–50.0 %) in 2006 to 84.2 % (95 %
CI, 80.3–87.5 %) in 2013 (Fig. 4). Compared to the base-
line (API in 2006), the IRR was only 0.05 (95 % CI,
0.04–0.05) in 2013 (Table 4), which equates to a
reduction of the malaria burden by 95.0 %. These indi-
cate major progress towards elimination.
The director of the Health Bureau of Mang Shi City,
the former headmaster of Zhe Fang Middle School said
that “The project had made impressive progress in redu-
cing the malaria burden. Malaria transmission among
school children has been a major problem prior to the
intervention; but malaria was scarcely following the im-
plementation of the GFATM programs”.
Malaria was accounted for 40–50 % of total communic-
able diseases prior to the intervention. Stakeholders in
both Mengla County and Jinghong City listed malaria as
the most important public health problem before the
GFATM program. Notably, they had difficulty to rank mal-
aria at all after the intervention. Stakeholders in Mengla
Fig. 3 Annual parasite incidences (API) in the five special regions of Myanmar from 2008 to 2013, based on Health Information System of HPA
Table 3 Change of annual parasite incidence rate ratios based on project reports in five special regions of Myanmar from 2008 to 2013














2008 (Baseline, n = 195 849) 2 765 Reference – 5 409 Reference – 8 174 Reference –
2009 (n = 544 876) 3 680 0.48 (0.46–0.50) <0.0001 6 738 0.45 (0.43–0.46) <0.0001 10 455 0.46 (0.45–0.47) <0.0001
2010 (n = 554 143) 2 798 0.36 (0.34–0.38) <0.0001 2 279 0.15 (0.14–0.16) <0.0001 5 084 0.22 (0.21–0.23) <0.0001
2011 (n = 187 803) 873 0.33 (0.31–0.36) <0.0001 526 0.10 (0.09–0.11) <0.0001 1 413 0.18 (0.17–0.19) <0.0001
2012 (n = 308 067) 1 251 0.29 (0.27–0.31) <0.0001 860 0.10 (0.09–0.11) <0.0001 2 111 0.16 (0.16–0. 17) <0.0001
2013 (n = 626 125) 3 181 0.36 (0.34–0. 38) <0.0001 1 279 0.07 (0.07–0. 08) <0.0001 4 460 0.17 (0.16–0. 18) <0.0001
aThe GFATM stopped its Chinese operations between May and December, 2011, HPA’s Health Information System in the five special regions of Myanmar established
and maintained by the GFATM grants, could run only for four months (January to April), n = 4 X 563409/12 = 187803 person-years. In 2012, HPA spent the first half of
the year to recruit new staff and restore project activities, n = 6 × 572 678/12 = 286 339 person-years
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County said that “Malaria was no longer a public health
problem because there was only one or two locally in-
fected malaria cases each year in this county with a popu-
lation of 310 000”. However, stakeholders in Jinghong City
said that “Malaria was still a major public health problem
despite the fact that there were only from three to five
imported malaria cases each year. Existing malaria vectors,
cross-border migration of population and imported mal-
aria from neighboring countries may reestablish malaria
transmission again”.
As results of surveillance of drug sensitivity, six hundred
and three patients with Plasmodium vivax infections
treated with chloroquine were completed a 28 day follow-
up. The fever clearance time (FCT) and asexual parasite
clearance times (APCT) were, respectively, 22.2 ± 10.2 and
38.1 ± 12.6 h. A total of 594 (98.5 %, 95 % CI, 97.2–99.3 %)
were adequate clinical and parasitological response
(ACPR), and only nine (1.5 %, 95 % CI 0.7–2.8 %) patients
were late clinical failure (LCF). The proportions of ACPR
did not change significantly from 2008 to 2013 (X2 = 0.86,
P = 0.6496) [13]. Two hundred and forty three P. falcip-
arum malaria patients treated with DP were completed a
42 day follow-up. The FCT and APCT were, respectively,
36.5 ± 10.9 and 43.5 ± 11.8 h, and there was an increasing
trend of both FCT (F = 268.41, P < 0.0001) and APCT (F =
88.6, P < 0.0001) from 2007 to 2013. Eight (3.3 %, 95 % CI,
Fig. 4 Annual parasite incidences (API) and the proportions of imported malaria cases in 19 counties of China, from 2006 to 2013, based on
Chinese information system for disease control and prevention
Table 4 Change of annual parasite incidence rate ratios based on Chinese information system for disease control and prevention
across 19 counties of Yunnan Province, China, from 2006 to 2013














2006(Baseline, n = 4 521 402) 6 570 Reference – 2 197 Reference – 8 874 Reference –
2007 (n = 4 562 688) 3625 0.55 (0.53–0.57) <0.0001 1 209 0.55 (0.51–0.58) <0.0001 4 847 0.54 (0.52–0.56) <0.0001
2008 (n = 4 603 659) 2235 0.33 (0.32–0.35) <0.0001 665 0.30 (0.27–0.32) <0.0001 2 903 0.32 (0.31–0.34) <0.0001
2009 (n = 4 644 719) 1686 0.25 (0.24–0.26) <0.0001 595 0.26 (0.24–0.29) <0.0001 2 283 0.25 (0.24–0.26) <0.0001
2010 (n = 4 687 896) 1261 0.19 (0.17–0.20) <0.0001 570 0.25 (0.23–0.27) <0.0001 1 833 0.20 (0.19–0.21) <0.0001
2011 (n = 4 729 147) 732 0.11 (0.10–0.11) <0.0001 223 0.10 (0.08–0.11) <0.0001 956 0.10 (0.10–0.11) <0.0001
2012 (n = 4 770 122) 417 0.06 (0.05–0.07) <0.0001 137 0.06 (0.05–0.07) <0.0001 556 0.06 (0.05–0.06) <0.0001
2013 (n = 4 800 944) 342 0.05 (0.04–0.05) <0.0001 81 0.03 (0.03–0.04) <0.0001 423 0.05 (0.04–0.05) <0.0001
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1.4–6.4 %) patients present parasitaemias on day three after
medication; however they were spontaneous cure at day
four without further treatment. In total, two hundred and
forty one of 243 (99.2 %; 95 % CI, 97.1 - 99.9 %) patients
were ACPR. The proportions of ACPR did not change sub-
stantially from 2007 to 2013 (X2 = 2.81, P = 0.7288) [14].
Impact to health service system
In China, the services of malaria diagnosis, treatment,
and prevention for those who frequently travel across
the China-Myanmar border were strengthened. In the
five special regions of Myanmar, GFATM ensured that
all residents had access to free quality-assured primary
health care within two hours walking distance from their
homes.
GFATM-supported training enhanced capacity of HPA
staff, locally governmental health officers in Myanmar, and
CDC staff in China on malaria control and project manage-
ment. Four hundred and fifty-six received training in diag-
noses including microscopy and RDT, and administering
proper treatment. One thousand and forty community-
based workers including VMWs, MMWs and private prac-
titioners received training in using RDT for diagnoses and
dosing for malaria treatment. One thousand two hundred
and ninety-eight community peer educators were trained
to provide health education. Traditional birth attendants
(TBA) were also trained to distribute LLINs and give con-
sultation on malaria for pregnant women.
The interventions made a positive impact on basic
health services. In China, an employee of Dan Zhu Border
Malaria Post said that “the program had improved the
capacity of the village clinic”. In SR4 of Myanmar, both
the HPA manager and the director of the health bureau
said that “The local government had recruited and trained
health care workers prior to the GFATM projects. How-
ever, in a case without GFATM grants, loss of health
workers would collapse the local health service system”.
Reduced social inequality
Communities including migrants and ethnical minorities
along the China-Myanmar border are one of the vulnerable
groups in the region. As a fact, populations who are living
in malaria endemic areas are largely poor and marginalized,
and at a higher risk of malaria infection. These core inter-
ventions improved accessibility and quality of malaria con-
trol services for them. Healthcare was offered regardless of
gender. The VMWs and MMWs ensured communities in
remote and highly endemic areas access to the free diagno-
sis and treatment. The poorest and the most vulnerable
populations were given priority to receive LLINs with an
additional one given to a pregnant woman through TBAs.
Women were encouraged to actively participate in commu-
nity health education and social mobilization, development
of materials of information, education and communication
(IEC) and strategies of BCC. The results of a household
survey in KSR2 conducted between June and September of
2013, indicated that the bed net to person ratio reached
1:1.96 (i.e., more than one net for every two people), and
the LLIN to person ratio reached 1:2.52. People in the
poorest families were much more likely to sleep under
ITNs/LLINs than those in richer families [23]. These
showed the positive impact of these interventions in reduc-
tion of social inequality.
Discussion
The China-Myanmar border region was once among the
highest burden regions of malaria in the world. In 2003, a
malaria epidemic took place in Kokang Region, Myanmar.
One thousand three hundred and ninety-two new cases of
malaria and 125 deaths were detected across 30 villages in
three districts during 13 days,from the 7th to 19th, Novem-
ber [24]. In December 2007, an active case detection was
performed in Wa State, 453 febrile patients were found
and tested by microscopy. The slide positivity rate was
60 % (270/453) and 90.74 % (245/270) of parasites were P.
falciparum [25]. In October 2009, the parasite prevalence
rate of 23.3 % (36/159) was detected in school children
and the P. falciparum prevalence rate of was 14.5 % (23/
159) in KR1 [26].
The five special regions of Myanmar are one of the major
imported malaria sources in China. This situation seriously
impedes malaria elimination in China [24–27]. The re-
duced parasite prevalence rate and API showed that the
core interventions of the GFATM programs decreased
malaria burden by 89 % between 2008 and 2013 in
Myanmar (Fig. 2, Tables 2 and 3); and by 95 % between
2006 and 2013 in China (Fig. 3, Table 4). The number of
imported malaria cases had decreased by 92 %, from 4 340
in 2006 to 356 in 2013 in Yunnan Province of China. These
efforts have promoted malaria elimination in China.
P. falciparum resistance to artemisinin has been con-
firmed in the GMS, all countries except China [1], and
threatens control and elimination of malaria worldwide [10,
28]. Artemisinin resistance is rampant in Myanmar. The
country is considered the main route through which drug-
resistant P. falciparum will spread from Southeast Asia to
the Indian Subcontinent and then on to Africa [29, 30]. In
the China-Myanmar border areas, artemisinin was highly
efficacious for the treatment of falciparum malaria by 2013
[14, 31, 32] and molecular markers of artemisinin resistance
was not found by 2012 [33, 34]. These results indicate that
these core interventions have prevented the development
and spread of artemisinin resistance.
Huang et al. reported kelch13 propeller domain muta-
tions in P. falciparum that was sampled from China-
Myanmar border during 2009–2012 [35], however, the
K13-propeller mutation was not detected in P. falcip-
arum that was sampled from 2013 (unpublished data)
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to2014 [36]. The relative prevalence of P. falciparum
parasites carrying K13-propeller mutations was investi-
gated in 55 sites of ten administrative regions in
Myanmar. K13-propeller mutation was discovered in
most parts of Myanmar except China-Myanmar border
[29]. Population size and genetic diversity of malaria par-
asites, and multi-clonal infections are correlated to the
spread of anti-malarial resistance as well as transmission
intensity [37]. Increasing access to quality-assured diag-
nosis and treatment with ACTs can limit drug resistance,
and can contribute to outcome improvement in patients
[38]. Most of these populations are ‘hill tribes’ on the
China-Myanmar border. Poor access to quality-assured
diagnosis and treatment gave rise to self-treatment and de-
layed standard treatment [22, 39]. The results of a cross-
sectional study showed that only 32.0 % of febrile patients
sought treatment within 24 h, while 79.6 % of febrile pa-
tients purchased anti-malarial drugs themselves from the
retail sector before the core interventions of the GFATM
programs [22]. Free quality-assured diagnosis and treat-
ment with ACTs to P. falciparum and the introduction of
regulations successfully beat the chaotic anti-malarial mar-
ket in the five special regions of Myanmar. BCC activities
improved knowledge and awareness about seeking qualified
treatment, and compliance with the standard treatment
regimen. These core interventions successfully prevented
drug resistance.
The China-Myanmar border is extremely porous. Chinese
official border crossing stations recorded 10 999 677
person-times of border crossings in 2009. Political isola-
tion has resulted in a lack of governmental health service
structure in the five special regions of Myanmar [17].
BMPs in China and MDTS integrated with private and
community-based facilities in Myanmar dramatically im-
proved malaria diagnosis and treatment service.
Myanmar staffs received training in China through the
project. This dramatically improved local and migrant ac-
cess to quality-assured health service. BMPs and MDTS
only provided malaria diagnoses and treatment before
July, 2009. Patients who did not have malaria were not in
position to receive any treatment of BMPs and MDTS.
This led to fewer and fewer febrile patient visiting BMPs
and MDTS. To ensure these facilities working effectively,
BMPs and MDTS were expanded into public health facil-
ities. The improvement in primary healthcare attracted fe-
brile patients to visit these facilities.
Malaria Control along the international border can
easily be affected by the political climate. In this pro-
ject, an international NGO, HPA, implemented core in-
terventions in the five Special Regions of Myanmar
with financial support from GFATM and technical as-
sistance from China under an agreement between
China and Myanmar. This simplified the process and
ensured carrying out these prompt and efficacious core
interventions by avoiding complexity required for dip-
lomatic coordination.
The study presents several limitations too. First, the
evaluation was unable to address potential confounding, e.
g. socioeconomic development, climate change and defor-
estation. However, China-Myanmar border was ever a high
malaria transmission area [1, 2]. These intensive control
efforts played a dominant role in the change of the malaria
situation. Second, Global Fund R6 and R10 were control
projects. The requirement of covering as many areas as
possible did not permit to use control groups. This leads
to difficult to clearly link the declined API to each special
intervention. Third, there were no appropriate govern-
mental health service structures prior to the GFATM pro-
jects in the five Special Regions of Myanmar. HPA could
only carry out some of these core interventions in parts of
target areas because of a lack of trained staff and logistics
in the first two project years. Some data such as the num-
ber of cases treat with CQ-PQ were unavailable in 2007,
and only 193 cases of P. vivax malaria were treated in
2008. Fourth, the epidemiological data were sparse in five
Special Regions of Myanmar prior to the intervention.
Available data were mainly collected by the HPA’s Health
Information System. This leads to the number of malaria
cases detected was fewer in 2008 than in 2009 because of
the fact that the project did not completely cover all pro-
ject areas in Myanmar in 2008. The system could only run
for four months (January-April) because the GFATM
abruptly stopped its China operations for eight months in
2011. HPA spent the first half of the year to recruit new
staff and restored project activities, the project could only
operate for six months (July to December) in 2012
(Table 3). API was also calculated as an indicator for evalu-
ation in spite of this situation. A cross-sectional survey of
parasite prevalence was undertaken to compensate for the
limitation every year. Fifth, the cross-sectional survey of
parasite prevalence was conducted from January to March
when malaria transmission was lower during 2008–2011,
and from September to November when malaria transmis-
sion was higher during 2012–2013 (Table 2). However, if
anything, this time limitation of the cross-sectional surveys
may just underestimate the impact of core interventions
on malaria burden.
Conclusions
In conclusion, integrated approaches reduced about 90 %
of malaria burden on the China-Myanmar border. The
intervention contributed to malaria elimination in China
and containment of artemisinin resistance. Meanwhile, it
strengthened the healthcare system and reduced social in-
equity of marginalized populations. However, further re-
gional efforts and funding for cross-border interventions
are still needed to achieve malaria elimination along the
international border.
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